Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oligonucleotide with breast carcinoma treating function

An oligonucleotide, breast cancer technology, applied in gene therapy, medical preparations containing active ingredients, organic chemistry, etc., can solve problems such as difficulty in obtaining satisfactory curative effects, and achieve the effect of stimulating immune cell proliferation

Inactive Publication Date: 2012-07-04
CHANGCHUN HUAPU BIOTECHNOLOGY CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many treatment modalities for breast cancer, it is difficult to achieve satisfactory results when applied alone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligonucleotide with breast carcinoma treating function
  • Oligonucleotide with breast carcinoma treating function
  • Oligonucleotide with breast carcinoma treating function

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1 Oligonucleotide (ODN) stimulates the proliferation of human peripheral blood mononuclear cells

[0049] 1. Isolation of Human Peripheral Mononuclear Cells

[0050] (1), equipment, equipment, reagents and materials

[0051] Low-temperature refrigerator, carbon dioxide incubator, ultra-clean bench, inverted microscope, cell culture bottle, blood cell counter, horizontal centrifuge, sampler, dropper of various specifications, etc.

[0052] ODN: All were synthesized by Takara Company, OPC grade, and their phosphate backbones were all thio-modified unless otherwise specified. It was dissolved in PBS (for the recipe, refer to "Molecular Cloning Experiment Guide (Third Edition)"), and quantified by an ultraviolet spectrophotometer.

[0053] Heparin-anticoagulated human peripheral blood leukocytes: Changchun Central Blood Station.

[0054] Polydextrose-diatrizoate: specific gravity 1.077±0.001, Beijing Dingguo Biotechnology Company.

[0055] RPMI1640 culture solut...

Embodiment 2

[0076] Example 2 Stimulation of oligonucleotides (ODN) to mouse splenocyte proliferation

[0077] 1. Isolation of Mouse Splenocytes

[0078] (1) Instruments, equipment, equipment, reagents and materials:

[0079] Low-temperature refrigerator, carbon dioxide incubator, ultra-clean workbench, inverted microscope, liquid nitrogen tank, cell culture bottle, hemocytometer, horizontal centrifuge, sampler, 200-mesh filter, droppers of various specifications, etc.

[0080] Red blood cell lysate: Weigh KHCO 3 1g, EDTA.Na 2 37.2g, NH 4 Cl 8.29g, add 800ml of water, adjust the pH value to 7.2-7.4, add water to 1L, and filter to sterilize.

[0081] RPMI1640 culture medium: same as above.

[0082] C57 / BL, BALB / c and Kunming mice: all were purchased from Beijing Weitong Lihua Company.

[0083] The ODNs adopted are YW101, YW102, 1585, 1826 and C274. 1585, 1826 refers to CpG 1585 (Heidi H. van Ojik, et al. CpG-A and B Oligodeoxynucleotides Enhance the Efficacy of Antibody Therapy by A...

Embodiment 3

[0101] Example 3 Activation of oligonucleotides (ODN) on human peripheral blood B cells, NK cells and monocytes

[0102] 1. Isolation of human peripheral mononuclear cells: the method is the same as above.

[0103] 2. ODN-stimulated human peripheral blood mononuclear cell activation experiment

[0104] Human peripheral blood mononuclear cells were cultured in RPMI 1640 containing 10% fetal bovine serum in a 24-well plate, 3×10 6 cells / well. Set up the experimental group and the control group, the experimental group added ODN YW101, YW102, the control group added 2216, 2006, C274 respectively. The final concentration of ODN in each group of culture wells was 3 μg / ml, and its sequence was as above.

[0105] After 18 hours of ODN action, the cells were stained with PE-labeled CD19, CD56 and CD14 antibodies produced by BD Company (USA) and FITC-labeled CD69. The specific method is: incubate the cells with PE-labeled antibody and FITC-labeled CD69 at 4° C. in the dark for 30 mi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an oligonucleotide, which can stimulate proliferation and activation of vitro immune cells. Animal experiments show that the oligonucleotide can be used for the prevention and treatment of breast cancer. The oligonucleotide can be used to prepare the preparation agents for the prevention or treatment of human breast cancer.

Description

Technical field: [0001] The invention relates to an oligonucleotide and its use for treating breast cancer. Background technique [0002] Breast cancer (mammary carcinoma) is a malignant tumor that occurs in the epithelial tissue of the mammary gland. It is one of the most common malignant tumors in women around the world. The incidence of breast cancer in my country is second only to cervical cancer, with a population incidence of 23 / 100,000; it accounts for 7-10% of all kinds of malignant tumors in the whole body. [0003] There are many treatment methods and measures for breast cancer, including surgery, radiotherapy, chemotherapy, endocrine therapy and biological therapy. Surgical treatment is currently the main method of breast cancer treatment, and the curative effect is better for early breast cancer without axillary lymph node metastasis; radiotherapy is usually used after surgery to prevent local recurrence, for isolated local recurrence lesions, and breast cancer ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07H21/04A61K48/00A61K31/7088A61P35/00
Inventor 王丽颖杨亮于永利
Owner CHANGCHUN HUAPU BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com